Seeking Alpha
 

Stryker Corporation (SYK)

- NYSE
  • Tue, Apr. 21, 6:16 PM
    • Stryker (NYSE:SYK) Q1 results ($M): Total Revenues: 2,379 (+3.2%); Net Income: 224 (+220.0%); GAAP EPS: 0.58 (+222.2%); CF Ops: 380 (+84.5%); Quick Assets: 4,263 (+5.3%).
    • Sales by segment: Orthopedics: 1,023 (+2.4%), Knees: 345 (-0.9%), Hips: 312 (-1.9%), Trauma & Extremities: 313 (+8.7%); Medsurg: 927 (+4.6%), Instruments: 346 (+0.9%), Endoscopy: 321 (+2.9%), Medical: 205 (+13.3%); Neurotech & Spine: 429 (+2.1%), Neurotechnology: 252 (+3.7%), Spine: 177 (0.0%).
    • Medsurg sales growth has decelerated the past three quarters: 23.6%, 16.3%, 12.1%, 4.6%.
    • Q2 Guidance: Non-GAAP EPS: $1.15 - 1.20.
    • 2015 Guidance: Organic sales growth: 5 - 6%; Non-GAAP EPS: $4.95 - 5.10 from $4.90 - 5.00.
    • If foreign currency exchange rates remain unchanged, sales in Q2 and 2015 will be negatively impacted by 3.5 - 4.5% and non-GAAP EPS by $0.25 - 0.30, half of which will be in H1.
    | Comment!
  • Tue, Apr. 21, 4:49 PM
    • Stryker (NYSE:SYK): Q1 EPS of $1.11 beats by $0.03.
    • Revenue of $2.38B (+3.5% Y/Y) in-line.
    • Press Release
    | Comment!
  • Tue, Apr. 21, 1:34 PM
    • Stryker (SYK +1.3%) will report Q1 results after today's close. Consensus view is EPS of $1.08 on revenues of $2.4B.
    | Comment!
  • Mon, Apr. 20, 5:35 PM
  • Wed, Apr. 8, 1:38 PM
    • Cytori Therapeutics (CYTX -1.5%) rated Buy with a $7 (425% upside) price target by Maxim Group.
    • Sagent Pharmaceuticals (SGNT +9.2%) rated Buy with a $29 (13% upside) price target by Deutsche Bank.
    • Mylan (MYL +15.6%) rated Overweight with a $70 (2% upside) price target by JP Morgan.
    • Akorn (AKRX +3.7%) rated Buy with a $55 (11% upside) price target by Deutsche Bank.
    • OvaScience (OVAS +1.4%) rated Outperform with a $60 (102% upside) price target by Oppenheimer.
    • Impax Laboratories (IPXL +3.2%) rated Hold with a $50 (flat) price target by Deutsche Bank.
    • Catamaran (CTRX) downgraded to Hold with a $61.50 (4% upside) price target by Jefferies.
    • NewLink Genetics (NLNK +4.4%) downgraded to Hold with a $50 (11% downside risk) price target by Jefferies.
    • Stryker (SYK +0.4%) downgraded to Underweight with a $92 (flat) price target by Barclays.
    | 5 Comments
  • Thu, Apr. 2, 1:23 PM
    • Retrophin (RTRX +3.7%) rated Outperform with a $48 (98% upside) price target by Leerink Partners.
    • OvaScience (OVAS +8.7%) rated Outperform with a $60 (82% upside) price target by Oppenheimer.
    • OxiGENE (OXGN -0.7%) rated Buy with a $6 (314% upside) price target by H.C. Wainwright.
    • Esperion Therapeutics (ESPR -4.5%) rated Buy with a $140 (40% upside) price target by UBS.
    • Trevena (TRVN -2.3%) rated Outperform with a $15 (110% upside) price target by Wedbush.
    • NewLink Genetics (NLNK -2.3%) downgraded to Hold with a $50 (4% downside risk) price target by Jefferies.
    • Stryker (SYK +0.2%) downgraded to Underweight with a $92 (1% upside) price target by Barclays.
    • Universal Health Services (UHS +2.7%) downgraded to Underperform with a $98 (16% downside risk) price target by Sterne Agee.
    | 3 Comments
  • Tue, Mar. 3, 8:58 AM
    • Stryker's (NYSE:SYK) Board of Directors authorizes a new $2B share repurchase program. Combining the $583M remaining under the existing authorization brings the total buyback amount up to $2.583B.
    | Comment!
  • Mon, Feb. 9, 5:37 PM
    | 8 Comments
  • Mon, Feb. 9, 12:21 PM
    • The following are healthcare companies whose after-tax margins have expanded the past three quarters and trade at least 500K shares per day:
    • (ACOR -0.7%)(BCR -1.5%)(BIIB -0.2%)(CAH -1.2%)(CPHD +1.3%)(EVHC -1.6%)(ILMN +0.7%)(JAZZ -1.7%)(LCI +7.3%)(MNK -0.5%)(SHPG -2.9%)(SYK -0.2%)(TMO -0.7%)(UTHR +1.4%)(VRX).
    • This is not a list of "Buy" recommendations, but rather a targeted list of firms that may be suitable for more in-depth research.
    | 3 Comments
  • Wed, Jan. 28, 1:54 AM
    • "We do plan to put our money to work," announced Stryker (NYSE:SYK) CEO Kevin Lobo on the company's Q4 earnings conference call. "Right now we are pursuing the acquisition deal flow, and we'll see what happens."
    • The company was recently rumored to have been preparing a bid for Smith & Nephew, although he gave no hint that any sort of deal was imminent.
    • Q4 net income fell 33% to $260M, hurt by costs for product recalls and a new regional headquarters in Europe.
    • SYK -0.4% AH
    | Comment!
  • Tue, Jan. 27, 4:54 PM
    • Stryker (NYSE:SYK): Q4 EPS of $1.44 misses by $0.01.
    • Revenue of $2.62B (+6.1% Y/Y) in-line.
    • Press Release
    | Comment!
  • Tue, Jan. 27, 4:23 PM
    • Stryker (NYSE:SYK) Q4 results ($M): Revenues: 2,618 (+6.1%), U.S.: 1,818 (+11.1%), Intl: 800 (-3.8%); COGS: 892 (+4.7%); R&D Expense: 153 (+10.1%); SG&A Expense: 1,059 (+4.7%); Net Income: 260 (-32.6%); EPS: 0.67 (-33.7%); CF Ops: 675 (+0.4%); Quick Assets: 5,000 (+25.6%).
    • Gross Profit: 1,726 (+6.8%); COGS: 34.1% (-1.3%); Gross Margin: 65.9% (+0.7%); Operating Earnings: 514 (+10.3%); Operating Earnings Yield: 19.6% (+4.0%); Net Earnings Yield: 9.9% (-36.5%).
    • Sales by segment: Orthopedics: 1,110 (+1.7%), Knees: 363 (-2.2%), Hips: 331 (-2.9%), Trauma & Extremities: 335 (+9.1%); Medsurg: 1,054 (+12.1%), Instruments: 393 (+12.3%), Endoscopy: 390 (+10.8%), Medical: 218 (+16.0%); Neurotech & Spine: 454 (+3.9%), Neurotechnology: 262 (+9.2%), Spine: 192 (-2.5%).
    • Q1 Guidance: Non-GAAP EPS: $1.05 - 1.10.
    • 2015 Guidance: Organic sales growth: 4.5 - 6.0%; Non-GAAP EPS: $4.90 - 5.00.
    | Comment!
  • Mon, Jan. 26, 5:35 PM
  • Tue, Jan. 13, 6:57 PM
    • Stryker (NYSE:SYK) expects to report Q4 EPS of $1.43-$1.45, below a $1.46 consensus. Net sales growth rose 6.1% (8.6% at constant currency) to $2.6B, below a $2.63B consensus.
    • Orthopaedics sales rose 1.7%, MedSurg 12.1%, and Neurotechnology & Spine 3.9%. Organic sales growth was 5.5%. U.S. sales +11.1% to $1.8B; international -3.8% to $800M (+3.8% in constant currency).
    • The medical device maker also says it now expects forex to have a $0.20 impact on 2015 EPS, worse than prior guidance of $0.10-$0.12.
    • SYK -1.3% AH. Full Q4 results arrive after the close on Jan. 27.
    | Comment!
  • Mon, Jan. 5, 9:35 AM
    • Stryker (SYK -1%) acquires privately-held CHG Hospital Beds in an all-cash transaction for an undisclosed sum. CHG makes low-height hospital beds and accessories that reduce the risk of patient falls.
    | 1 Comment
  • Dec. 24, 2014, 1:19 PM
    • Osiris Therapeutics (NASDAQ:OSIR) establishes a partnership with Stryker (NYSE:SYK) to develop and commercialize Osiris' BIO4 bone matrix tissue form. Under the terms of the collaboration agreement, Stryker has an exclusive worldwide license to BIO4 and is responsible for all commercialization activities. Osiris is responsible for the manufacturing and continued research and product improvement efforts. Both firms will collaborate on the design and conduct of future clinical trials.
    • BIO4 is a bone allograft that contains both viable cells and growth factors.
    • Specific financial terms of the partnership are undisclosed.
    | Comment!
Visit Seeking Alpha's
SYK vs. ETF Alternatives
Company Description
Stryker Corporation is a medical technology company. The Company offers medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products.